JP Morgan Upgrades Camp4 Therapeutics to Overweight, Raises Price Target to $9
Benzinga Newsdesk 4 months ago
NewsUpgradesPrice TargetAnalyst Ratings
JP Morgan analyst Anupam Rama upgrades Camp4 Therapeutics (NASDAQ:CAMP) from Neutral to Overweight and raises the price target from $5 to $9.
JP Morgan analyst Anupam Rama upgrades Camp4 Therapeutics (NASDAQ:CAMP) from Neutral to Overweight and raises the price target from $5 to $9.